Markers of muscarinic deficit for individualized treatment in schizophrenia
Recent clinical studies have shown that agonists at muscarinic acetylcholine receptors effectively reduce schizophrenia symptoms. It is thus conceivable that, for the first time, a second substance class of procholinergic antipsychotics could become established alongside the usual antidopaminergic a...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2022.1100030/full |
| _version_ | 1797957447878443008 |
|---|---|
| author | Heiner Stuke Heiner Stuke |
| author_facet | Heiner Stuke Heiner Stuke |
| author_sort | Heiner Stuke |
| collection | DOAJ |
| description | Recent clinical studies have shown that agonists at muscarinic acetylcholine receptors effectively reduce schizophrenia symptoms. It is thus conceivable that, for the first time, a second substance class of procholinergic antipsychotics could become established alongside the usual antidopaminergic antipsychotics. In addition, various basic science studies suggest that there may be a subgroup of schizophrenia in which hypofunction of muscarinic acetylcholine receptors is of etiological importance. This could represent a major opportunity for individualized treatment of schizophrenia if markers can be identified that predict response to procholinergic vs. antidopaminergic interventions. In this perspective, non-response to antidopaminergic antipsychotics, specific symptom patterns like visual hallucinations and strong disorganization, the presence of antimuscarinic antibodies, ERP markers such as mismatch negativity, and radiotracers are presented as possible in vivo markers of muscarinic deficit and thus potentially of response to procholinergic therapeutics. Finally, open questions and further research steps are outlined. |
| first_indexed | 2024-04-11T00:04:11Z |
| format | Article |
| id | doaj.art-36a63521245446ee8ee366b02f67c09f |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-04-11T00:04:11Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-36a63521245446ee8ee366b02f67c09f2023-01-09T13:22:39ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402023-01-011310.3389/fpsyt.2022.11000301100030Markers of muscarinic deficit for individualized treatment in schizophreniaHeiner Stuke0Heiner Stuke1Department of Psychiatry and Psychotherapy, Charité—Universitätsmedizin Berlin, Berlin, GermanyBerlin Institute of Health at Charité—Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, Berlin, GermanyRecent clinical studies have shown that agonists at muscarinic acetylcholine receptors effectively reduce schizophrenia symptoms. It is thus conceivable that, for the first time, a second substance class of procholinergic antipsychotics could become established alongside the usual antidopaminergic antipsychotics. In addition, various basic science studies suggest that there may be a subgroup of schizophrenia in which hypofunction of muscarinic acetylcholine receptors is of etiological importance. This could represent a major opportunity for individualized treatment of schizophrenia if markers can be identified that predict response to procholinergic vs. antidopaminergic interventions. In this perspective, non-response to antidopaminergic antipsychotics, specific symptom patterns like visual hallucinations and strong disorganization, the presence of antimuscarinic antibodies, ERP markers such as mismatch negativity, and radiotracers are presented as possible in vivo markers of muscarinic deficit and thus potentially of response to procholinergic therapeutics. Finally, open questions and further research steps are outlined.https://www.frontiersin.org/articles/10.3389/fpsyt.2022.1100030/fullschizophreniapsychosismuscarinic receptorpersonalized medicineacetylcholineantipsychotics |
| spellingShingle | Heiner Stuke Heiner Stuke Markers of muscarinic deficit for individualized treatment in schizophrenia Frontiers in Psychiatry schizophrenia psychosis muscarinic receptor personalized medicine acetylcholine antipsychotics |
| title | Markers of muscarinic deficit for individualized treatment in schizophrenia |
| title_full | Markers of muscarinic deficit for individualized treatment in schizophrenia |
| title_fullStr | Markers of muscarinic deficit for individualized treatment in schizophrenia |
| title_full_unstemmed | Markers of muscarinic deficit for individualized treatment in schizophrenia |
| title_short | Markers of muscarinic deficit for individualized treatment in schizophrenia |
| title_sort | markers of muscarinic deficit for individualized treatment in schizophrenia |
| topic | schizophrenia psychosis muscarinic receptor personalized medicine acetylcholine antipsychotics |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2022.1100030/full |
| work_keys_str_mv | AT heinerstuke markersofmuscarinicdeficitforindividualizedtreatmentinschizophrenia AT heinerstuke markersofmuscarinicdeficitforindividualizedtreatmentinschizophrenia |